[{"from": "human", "value": "Please give me some details about this molecule. [C][C@@H1][Branch2][=Branch1][C][C][=C][C][=C][N][C][Ring1][=Branch1][=N][C][=Branch1][Ring2][=C][Ring1][Branch1][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][C@@H1][Branch1][=N][C][N][C][=Branch1][C][=O][C][N][Branch1][C][C][C][N][C][=Branch1][C][=O][C][=C][C][=Branch1][=C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][Branch1][C][C][C][Cl][O]"}, {"from": "gpt", "value": "The molecule is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline (GSK). GSK-923295 demonstrated a broad spectrum of activity against a range of human tumor xenografts grown in nude mice, including models of colon, breast, ovarian, lung and other tumors. GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK."}]